Phase III Daclatasvir and Sofosbuvir for Genotype 3 Chronic HCV (ALLY 3)

To study the combination of Daclatasvir and Sofosbuvir for the treatment of HCV Genotype 3 infection


Study Type: Interventional
Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 3 Evaluation of Daclatasvir and Sofosbuvir in Treatment Naive and Treatment Experienced Subjects With Genotype 3 Chronic Hepatitis C Infection
Enrollment: 152
Study Start Date: January 2014
Study Completion Date: December 2014
Primary Completion Date: September 2014 (Final data collection date for primary outcome measure)

Arms:
- Experimental: A1:Daclatasvir + Sofosbuvir in treatment-naive subjects
- Experimental: A2:Daclatasvir + Sofosbuvir in treatment-experienced subjects